Antibiotics are lifesaving therapeutic drugs that have been used by human for decades. They are used both in the fight against bacterial pathogens for both human and for animal feeding. However, of recent, their effects on the gut microbial compositions and diversities have attracted much attention. Existing literature have established the dysbiosis (reduced diversity) in the gut microbiota in association with antibiotic and antibiotic drug doses. In the light of spelling out the varying effects of antibiotic use on gut microbiota, this review aimed at given an account on the degree of gut microbial alteration caused by common antibiotics. While some common antibiotics are found to destroy the common phyla, other debilitating effects were observed. The effects can be attributed to the mode of mechanism, the class of antibiotic, the degree of resistance of the antibiotic used, the dosage used during the treatment, the route of administration, the pharmacokinetic and pharmacodynamics properties and the spectrum of the antibiotic agent. Health status, stress or the type of diet an individual feeds on could be a great proportion as confounding factors. While it is understood that only the bacterial communities are explored in the quest to establishing the role of gut in health, other gut microbial species are somehow contributing to the dysbiosis status of the gut microbiota. Until now, long term natural fluctuations like diseases outbreaks and mutations of the strain might as well rendered alteration to the gut independent of antibiotic treatments.

Rapid deforestation and unprecedented wildlife trafficking are important factors triggering the rate of zoonotic spillover from animals to humans. Consequently, this leads to the emergence and re-emergence of zoonotic infectious diseases among the human population. Deforestation is an important ecological disruption that leads to the loss of biodiversity. The loss of biodiversity results in the persistence of highest-quality hosts of zoonotic pathogens dominating the low-diversity communities, a process termed the dilution effect. Activities like intensive farming and logging that resulted in deforestation bring vulnerable people in close contact with these highest-quality reservoir hosts (wildlife). As a result of this vulnerability, there is an increased risk of spillover, leading to zoonotic infection in humans and eventually disease outbreaks during human–human transmission. One prominent example of a disease of wildlife origin is the ongoing SARS-CoV-2 (Severe Acute Respiratory Syndrome-Coronavirus 2), even though the original source has not been found. Another important factor facilitating the risk of spillover and emergence of zoonotic infectious diseases is wildlife trafficking. This involves illegal hunting and trading of wildlife and their products, which increases the risk of spillover as a result of exchange of bodily fluids and bloodmeals between humans and wildlife during the hunting and butchering of animals’ carcasses. Consequently, little or no hygiene protocol and poor handling practices during the wildlife-trade chain expose poachers, consumers, and local market sellers to the risk of zoonotic diseases. Despite the interventions on deforestation-induced spillover and wildlife trafficking-associated spillover, there are still knowledge and research gaps that need to be addressed towards preventing the outbreaks of future zoonotic infectious diseases. In response to this, there is a need for interdisciplinary and intersectoral collaborations among researchers from various fields as well as sectors in minimizing the risk of zoonotic spillover driven by deforestation and wildlife trafficking at the human–animal–environmental nexus. In addition, there is a need for integrated and unified evidence-based policy formulation that puts an end to deforestation and wildlife trafficking, especially in tropical areas such as Africa and Asia.

The contribution of dysbiotic gut microbiota configuration is essential when making reference to the metabolic disorders by increasing energy. It is important to understand that the gut microbiota induced metabolic disease mechanisms and inflammations. Thus it is imperative to have an insight into the state of all chronic subclinical inflammations influencing disease outcomes. However, from the emerging studies, there still exist inconsistencies in the findings of such studies. While making the best out of the reasons for inconsistencies of the findings, this review is designed to make a clear spell out as to the inconsistence of gut microbiota with respect to diabetes. It considered gut-virome alterations and diabetes and gut-bacteriome-gut-virome-alterations and diabetes as confounding factors. The review further explained some study design strategies that will spontaneously eliminate any potential confounding factors to lead to a more evidence based diabetic-gut microbiota medicine. Lipopolysaccharide (LPS) pro-inflammatory, metabolic endotoxemia and diet/gut microbiota insulin-resistance and low-grade systemic inflammation induced by gut microbiota can trigger pro-inflammatory cytokines in insulin-resistance, consequently, leading to the diabetic condition. While diet influences the gut microbiota, the consequences are mainly the constant high levels of pro-inflammatory cytokines in the circulatory system. Of recent, dietary natural products have been shown to be anti-diabetic. The effects of resveratrol on the gut showed an improved lipid profile, anti-inflammatory properties and ameliorated the endotoxemia, tight junction and glucose intolerance.

Background: Human myiasis is a parasitic dipteran fly infestation that infects humans and vertebrates worldwide. However, the disease is endemic in Sub-Saharan Africa and Latin America. In Sub-Saharan Africa, it is under-reported and therefore its prevalence is unknown. This systematic review aims to elucidate the prevalence of human myiasis, factors that influence the infection, and myiasis-causing fly species in SSA. The review also dwelled on the common myiasis types and treatment methods of human myiasis.Methods: Here, we collect cases of human myiasis in Sub-Saharan Africa based on literature retrieved from PubMed, Google Scholar and Science Direct from 1959 to 2022. A total of 75 articles and 157 cases were included in the study. The recommendations of PRISMA 2020 were used for the realization of this systematic review.Results: In total, 157 cases of human myiasis in SSA were reviewed. Eleven fly species (Cordylobia anthropophaga,Cordylobia rodhaini,Dermatobia hominis,Lucilia cuprina,Lucilia sericata,Oestrus ovis,Sarcophagaspp.,Sarcophaga nodosa,Chrysomya megacephala,Chrysomya chloropygaandClogmia albipuntum) were found to cause human myiasis in SSA.Cordylobia anthropophagawas the most prevalent myiasis-causing species of the reported cases (n = 104, 66.2%). More than half of the reported cases were from travelers returning from SSA (n = 122, 77.7%). Cutaneous myiasis was the most common clinical presentation of the disease (n = 86, 54.7%). Females were more infected (n = 78, 49.6%) than males, and there was a higher infestation in adults than young children.Conclusion: The findings of this study reveals that international travelers to Sub-Saharan Africa were mostly infested therefore, we recommend that both international travelers and natives of SSA be enlightened by public health officers about the disease and its risk factors at entry points in SSA and the community level respectively. Clinicians in Sub-Saharan Africa often misdiagnose the disease and most of them lack the expertise to properly identify larvae, so we recommend the extensive use of molecular identification methods instead.

Despite legislative enforcement on authorized drugs, off‑label and unapproved pediatric drug use is prevalent. The present study aimed to assess the global prevalence of off‑label and unlicensed prescriptions among hospitalized children via meta‑analysis. A comprehensive examination of articles published between 1990 and 2023 from the PubMed, Scopus, Excerpta Medica Database, Web of Science and Google Scholar databases was conducted. Key word‑based advanced searches were executed using the aforementioned databases. A total of 45 studies that reported the prescriptions of off‑label and unlicensed drugs to pediatric patients were included. The global prevalence of off‑label and unlicensed drug prescriptions to children in pediatrics or neonatal departments was 56%. Patient sample sizes varied from 40‑13,426, with a range of 240‑8,891 total prescriptions issued. Of the 45 studies examined, 22 studies originated from Europe, 13 from Asia, 3 from South America, 3 from Africa, and 2 each from North America and Australia. Africa had the highest prevalence rate at 66%, followed by Asia, South America, North America, Australia and Europe. The present meta‑analysis demonstrated that the prevalence of off‑label and unlicensed drug prescriptions given to pediatric patients was notably high and geographically diverse. Therefore, drug authorities should standardize pediatric prescription practices in future.